Literature DB >> 23702713

Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission.

Linda A Feagins1, Shelby D Melton, Ramiz Iqbal, Kerry B Dunbar, Stuart J Spechler.   

Abstract

BACKGROUND: For patients with ulcerative colitis (UC) who have colonoscopy while their disease is in clinical remission, the clinical implications of finding histologic abnormalities of colitis are not clear.
METHODS: We reviewed the medical records of patients with UC who had elective colonoscopy at our VA Medical Center while their UC was in clinical remission and who had at least 6 months of follow-up data available. The Mayo endoscopic subscore was used to assess endoscopic disease activity. Biopsies were evaluated for specific changes in the following general categories: acute inflammation, chronic inflammation, epithelial damage, and architectural distortion.
RESULTS: We identified 51 patients with UC who had a total of 84 colonoscopies (at least 1 year apart) while they were in clinical remission. Forty colonoscopies revealed no endoscopic activity (Mayo subscore 0) and 44 showed endoscopic activity (Mayo subscore 1, 2, or 3). Although flares were approximately twice as common in patients with endoscopic activity as in those with an endoscopically normal mucosa, the difference was not statistically significant. On histologic evaluation, in contrast, the presence of basal lymphoplasmacytosis, basally located lymphoid aggregates, erosions and/or ulcerations of the epithelium, or moderate to marked architectural distortion all were significant predictors of clinical flares by 6 and 12 months.
CONCLUSIONS: For patients with UC who have colonoscopy while their disease is in clinical remission, colonic biopsy seems to provide important prognostic information beyond that provided by the endoscopic assessment of disease activity alone.

Entities:  

Mesh:

Year:  2013        PMID: 23702713     DOI: 10.1097/MIB.0b013e318281f4ae

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  9 in total

1.  Molecular patterns in human ulcerative colitis and correlation with response to infliximab.

Authors:  Brendan Halloran; Jessica Chang; David Q Shih; Dermot McGovern; Konrad Famulski; Chad Evaschesen; Richard N Fedorak; Aducio Thiesen; Stephan Targan; Philip F Halloran
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 2.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?

Authors:  Rish K Pai; Karel Geboes
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

3.  Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring.

Authors:  M H Collins; L J Martin; E S Alexander; J Todd Boyd; R Sheridan; H He; S Pentiuk; P E Putnam; J P Abonia; V A Mukkada; J P Franciosi; M E Rothenberg
Journal:  Dis Esophagus       Date:  2017-02-01       Impact factor: 3.429

4.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.

Authors:  Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-24       Impact factor: 11.382

5.  Raman spectroscopy of endoscopic colonic biopsies from patients with ulcerative colitis to identify mucosal inflammation and healing.

Authors:  James Addis; Noor Mohammed; Olorunda Rotimi; Derek Magee; Animesh Jha; Venkataraman Subramanian
Journal:  Biomed Opt Express       Date:  2016-04-27       Impact factor: 3.732

Review 6.  Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?

Authors:  Noor Mohammed; Venkataraman Subramanian
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

7.  Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease.

Authors:  Corinna Lang-Schwarz; Abbas Agaimy; Raja Atreya; Christoph Becker; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Michael Vieth
Journal:  Virchows Arch       Date:  2020-12-29       Impact factor: 4.064

8.  Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease.

Authors:  Corinna Lang-Schwarz; Miriam Angeloni; Abbas Agaimy; Raja Atreya; Christoph Becker; Theresa Dregelies; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Britta Siegmund; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Fulvia Ferrazzi; Michael Vieth
Journal:  J Crohns Colitis       Date:  2021-10-07       Impact factor: 9.071

9.  Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study.

Authors:  Ferdinando D'Amico; Gionata Fiorino; Virginia Solitano; Eugenia Massarini; Lucas Guillo; Mariangela Allocca; Federica Furfaro; Alessandra Zilli; Stefanos Bonovas; Fernando Magro; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  United European Gastroenterol J       Date:  2022-09-15       Impact factor: 6.866

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.